Amino Acid Composition for Traumatic Brain Injury Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for traumatic brain injury (TBI) are inadequate, as there is a need for effective therapeutics to address the disruption in brain function caused by acute external forces, with existing BCAA supplementation showing promise but requiring further development for human application.
Innovation Solution
A pharmaceutical composition comprising defined amino acid components, including leucine, isoleucine, valine, and other specific amino acids, administered with a pharmaceutically acceptable carrier, is provided for treating TBI, which can be formulated into various dosage forms for oral, topical, or parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCAA supplementation is used to treat TBI, then the therapeutic effect is improved, but the treatment is not yet sufficient for human application
Solution Approach 1:
The patent changes the parameters of amino acid supplementation by specifying exact compositions with defined ratios of BCAAs (leucine, isoleucine, valine) combined with other amino acids (arginine, glutamine, glycine, methionine, proline) at specific concentrations. This transforms the general BCAA supplementation approach into a precisely formulated pharmaceutical composition suitable for clinical use in TBI patients.
2Reliability
If a defined amino acid composition is developed for TBI treatment, then the treatment efficacy is improved, but the formulation complexity increases
Solution Approach 1:
The patent creates a composite amino acid formulation combining multiple amino acids (BCAAs: leucine, isoleucine, valine; plus arginine, glutamine, glycine, methionine, proline) in specific ratios. This composite approach leverages the synergistic effects of different amino acids to enhance treatment efficacy while managing formulation complexity through defined compositional parameters.
Data Source
AI summary
This disclosure provides pharmaceutical compositions comprising defined amino acid components, and methods for treating traumatic brain injury comprising administering an effective amount of the compositions to a subject in need thereof.